Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-Hodgkin's Lymphoma

Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)

Bone Marrow Transplantation volume 25, pages 957–964 (2000)Cite this article

Abstract

This is a report on 111 patients with advanced stage follicular lymphoma who where autografted using PBSC. Seventy patients were enrolled in first remission, whereas 41 were treated in second or higher remission. High-dose therapy consisted of total body irradiation plus cyclophosphamide in 103 patients, while eight patients received BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan). Autografts contained 8.1 ± 0.6 × 106 CD34+ cells/kg body weight. At a median follow-up of 44.2 months from PBSCT (range 4.9–77.4 months), 93 patients are alive, with a probability of overall and relapse-free survival (RFS) of 83% and 64%, respectively. A significantly higher probability of relapse was associated with male gender, involvement of more than eight lymph node areas, extra-nodal manifestations other than bone marrow and PBSCT performed in second or higher remission. In the latter group of patients, previous radiotherapy was associated with poor prognosis. The relevance of chemosensitivity as a prognostic factor was reflected by a better RFS in patients who had achieved complete remission at the time of PBSC mobilization. In a multivariate analysis, involvement of eight or more lymph nodes and high-dose therapy performed in second or higher remission were independent prognostic factors. Bone Marrow Transplantation (2000) 25, 957–964.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Rosenberg SA . Karnofsky memorial lecture. The low-grade non-Hodgkin’s lymphomas: challenges and opportunities J Clin Oncol 1985 3: 299–310

    Article  CAS  Google Scholar 

  2. Horning SJ . Treatment approaches to the low-grade lymphomas Blood 1994 834: 881–884

    Google Scholar 

  3. Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20 year study from a single center J Clin Oncol 1995 13: 140–147

    Article  CAS  Google Scholar 

  4. Hiddemann W, Unterhalt M, Herrmann R et al. Mantle cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group J Clin Oncol 1998 16: 1922–1930

    Article  CAS  Google Scholar 

  5. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin’s lymphoma New Engl J Med 1995 333: 1540–1545

    Article  CAS  Google Scholar 

  6. Rohatiner AZ, Johnson PW, Price CG et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma J Clin Oncol 1994 12: 1177–1184

    Article  CAS  Google Scholar 

  7. Haas R, Moos M, Karcher A et al. Sequential high dose therapy with peripheral blood progenitor cell support in low grade non-Hodgkin’s lymphoma J Clin Oncol 1994 12: 1685–1692

    Article  CAS  Google Scholar 

  8. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor prognosis follicular lymphoma Blood 1995 86: 3257–3262

    CAS  PubMed  Google Scholar 

  9. Freedman AS, Gribben JG, Neuberg D et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission Blood 1996 88: 2780–2786

    CAS  PubMed  Google Scholar 

  10. Vose JM, Bierman PJ, Lynch JC et al. Effect of follicularity on autologous transplantation for large cell non-Hodgkin’s lymphoma J Clin Oncol 1998 16: 844–849

    Article  CAS  Google Scholar 

  11. Voso MT, Hohaus S, Moos M et al. Autografting with CD34+ peripheral blood stem cells (PBSC): retained engraftment capability and reduced tumor cell content Br J Haematol 1999 104: 382–391

    Article  CAS  Google Scholar 

  12. Bierman PJ, Vose JM, Anderson JR et al. High dose therapy with autologous hematopoietic rescue for follicular low grade non Hodgkin’s lymphoma J Clin Oncol 1997 15: 445–450

    Article  CAS  Google Scholar 

  13. Romaguera JE, McLaughlin P, North L et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model J Clin Oncol 1991 9: 762–769

    Article  CAS  Google Scholar 

  14. Dana BW, Dahlberg S, Nathwani BN et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy J Clin Oncol 1993 11: 644–651

    Article  CAS  Google Scholar 

  15. Shipp MA, Harrington DP for the International Non-Hodgkin’s Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin’s lymphoma New Engl J Med 1993 329: 987–994

    Article  Google Scholar 

  16. Lopez-Guillermo A, Montserrat E, Bosch F et al. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma J Clin Oncol 1994 12: 1343–1348

    Article  CAS  Google Scholar 

  17. Moos M, Schulz R, Martin S et al. The remission status before and the PCR status after high dose therapy with peripheral blood stem cell support are prognostic factors for relapse free survival in patients with follicular non Hodgkin’s lymphoma Leukemia 1998 12: 1971–1976

    Article  CAS  Google Scholar 

  18. Zwicky CS, Maddocks AB, Andersen N, Gribben JG . Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin’s lymphoma is associated with decreased relapse after autologous bone marrow transplantation Blood 1996 88: 3314–3322

    CAS  PubMed  Google Scholar 

  19. Widmer L, Pichert G, Jost LM, Stahel RA . Fate of contaminating t(14;18)+ lymphoma cells during ex vivo expansion of CD34 selected hematopoietic progenitor cells Blood 1996 88: 3166–3175

    CAS  PubMed  Google Scholar 

  20. Vescio RA, Han EJ, Schiller GJ et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts Bone Marrow Transplant 1996 18: 103–110

    CAS  PubMed  Google Scholar 

  21. Leonard BM, Hetu F, Busque L et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources Blood 1998 91: 331–339

    CAS  PubMed  Google Scholar 

  22. Rohatiner A . Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem cell transplantation J Clin Oncol 1994 12: 2521–2523

    Article  CAS  Google Scholar 

  23. Kirkland MA, Spencer A, Davidson RJ et al. Quantitation of mafosfamide resistant pre-colony forming units in allogeneic bone marrow transplantation: relationship with rate of engraftment and evidence for long lasting reduction in stem cell numbers Blood 1996 87: 3963–3969

    CAS  PubMed  Google Scholar 

  24. Voso MT, Murea S, Goldschmidt H et al. High dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haematopoietic progenitor cell compartment Br J Haematol 1996 94: 759–766

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We wish to thank all the colleagues who during these years referred patients to our centre, the staff of the Transplantation Unit and of the Department of Radiology for the outstanding care of patients. The excellent technical assistance of Renate Alexi, Kirsten Flentje, Monika Hess, Evi Holdermann, Margit Pförsich, Petra Schmidt, Lena Volk and Mirjam Weis and the continuous secretarial help of Ursula Scheidler are also acknowledged.

Author information

Authors and Affiliations

  1. German Cancer Research Center, Heidelberg, Germany

    MT Voso & R Haas

  2. Department of Internal Medicine V, University of Heidelberg, Germany

    S Martin, S Hohaus, A Abdallah, RF Schlenk, AD Ho & R Haas

Authors
  1. MT Voso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Hohaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Abdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. RF Schlenk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. AD Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voso, M., Martin, S., Hohaus, S. et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 25, 957–964 (2000). https://doi.org/10.1038/sj.bmt.1702336

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702336

Keywords

This article is cited by

Search

Advanced search

Quick links